Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FLO Trial: Step-Wise Escalation for Pleural Infection
NCT07592520Phase 4Not yet recruiting
- Sponsor
- Dartmouth Health
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of Normal Saline-Benha University, tissue-plasminogen activator and dornase alfa in Complicated parapneumonic effusion (cPPE) and empyema, sponsored by Dartmouth Health. Primary endpoint: Time to chest tube removal at 7 days. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
Normal Saline-Benha Universitytissue-plasminogen activatordornase alfa
03
Conditions
Complicated parapneumonic effusion (cPPE)empyema
Beyond the preview
Go deeper on NCT07592520.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07592520.